By Natalie Weger
Indivior shares jumped after the pharmaceuticals company raised its full-year revenue guidance and swung to a second-quarter profit.
Shares earlier rose 21% to a fresh 52-week high of $21.01, and were recently trading at $19.47. The stock is now up 57% for the year.
Indivior on Thursday raised its full-year 2025 revenue guidance to between $1.03 billion and $1.08 billion, up from its previous guidance of $955 million to $1.03 billion.
Chief Executive Joe Ciaffoni said the company's Sublocade treatment's net revenue, and its Suboxone film's pricing stability, led the company to raise its guidance.
Indivior swung to a second-quarter profit of $18 million, or 14 cents a share, compared with a loss of $97 million, or 72 cents a share, in the same quarter last year.
Net revenue increased to $302 million, compared with $299 million in last year's comparable quarter. Analysts polled by FactSet expected $241.7 million.
Indivior also raised its outlook for adjusted earnings before interest, taxes, depreciation and amortization to between $275 million and $300 million, up from its previously issued guidance of $220 million to $260 million.
Write to Natalie Weger at natalie.weger@wsj.com
(END) Dow Jones Newswires
July 31, 2025 14:03 ET (18:03 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。